Evaluation of soluble intracellular adhesion molecule-I (slCAM-1) in benign and malignant ovarian masses

Purpose: To evaluate serum ICAM-1 levels preoperatively in patients with ovarian masses.

Methods: Estimation by ELISA assay in 101 women with pelvic tumours and 16 healthy controls was performed. Correlations of sICAM-1 levels with CA-125, Tumour Volume Index, morphological score and pathological findings were studied.

Results: Fifty-one ovarian tumours were malignant, five were borderline and 45 benign. Mean levels of sICAM-1 were respectively, 311.1 +/- 182.9 ng/ml, 172.6 +/- 40.1 ng/ml, 241.8 +/- 74.1 ng/ml and 195.6 +/- 68.7 ng/ml for controls. The area under ROC curve for sICAM-1 was 0.72 (95% CI 0.58-0.82), the cut-off 250 ng/ml, corresponding to 81.3% sensitivity and 52.9% specificity. Serum ICAM-1 correlated with morphological score (r = 0.51, p < 0.001), but not with FIGO stage, tumour grade, Tumour Volume Index and CA-125.

Conclusion: sICAM-1 concentrations are higher in patients with malignant tumours, but poorly correlate with clinical status. The clinical use alone in ovarian malignancy detection and tumour differentiation seems to have limited application. Combinations of CA-125 and sICAM-1 could improve the test characteristics.

ICAM-1; Ovarian; Cancer; Benign; Borderline tumour

[1] Kostler W.J., Tomek S., Brodowicz T. et al.: "Soluble ICAM-1 in breast cancer: clinical significance and biological implications". Cancer lmmunol. lmmunother., 2001, 50, 483.

[2] Sprenger A., Schardt C., Rotsch M. I. wsp.: "Soluble intracellular adhesion molecule-I in patients with lung cancer and benign lung disease". J. Cancer Res. Clin. Oneal., 1997, 123, 632.

[3] Kestler W.J., Tomek S., Brodowicz T. I. et al.: "Soluble ICAM-1 in breast cancer: clinical significance and biological implications". Cancer Immunol. Immunother., 2001, 50, 483.

[4] Kitagawa T., Matsumoto K., Iriyama K.: "Serum cell adhesion molecules in patients with colorectal cancer". Surg. Today, 1998, 28, 262.

[5] Nakata B., Hori T., Sunami T. I. et al.: "Clinical significance of serum soluble intracellular adhesion molecule I in gastric cancer". Clin. Cancer Res., 2000, 6, 1175.

[6] Boyano M.D., Garcia-Vazquez M.D., Lopez-Michelena T. I. et al.: "Soluble interleukin-2 receptor, intracellular adhesion molecule-1 and interleukin-IO serum levels in patients with melanoma". Br. J. Cancer, 2000, 83, 7, 847.

[7] Araki T., Mi灼C.,Kusunoki M.: "Biological implications of sirsulating soluble intracellular adesion molecule-I in colorectal cancer patients". Scand. J. Gastroenterol., 2001, 36, 399.

[8] F errazzi E., Zanetta G., Dordoni D. et al.: "Transvaginal ultrasonographic characterisation of ovarian masses: comparison of five scoring system in a multicenter study". Ultrasound Obstet. Gynecol., 1997, 10, 192.

[9] Metz C.E., Herman B.A., Roe C.A.: "Statistical comparison of two ROC curve estimates obtained from partially-paired datasets". Med. Decis. Making, 1998, 18, 110.

[10] Gho Y.S., Kim P.N., Li H.C. et al.: "Stimaulation of tumor growth by human soluble intracellular adhesion molecule-I". Cancer Res., 2001, 61, 4253.

[11] Callet N., Delunay J., Pichon M.F.: "Serum sICAM-1 (soluble intracellular adhesion molecule-I) and M-CSF (macrophage colony stimulating growth factor) throughout monitoring of 34 non-serous ovarian cancers". Eur. J. Gynaeco/. Oneal., 2000, 21, 2,135.

[12] Darai E., Bringuier AF., Walker-Combrouze F. et al.: "Soluble adhesion molecules in serum and cyst fluid from patients with cystic tumours of the ovary". Hum. Reprod., 1998, 13, 2831.